From the Genome to
the Clinic
The next wave in immuno-oncology
Therapeutic product discovery
In the information age

NEWS

ALL NEWS
DISCOVERY

DISCOVERY

Tel Aviv

Our optimized process for predictive discovery of novel drug targets
READ MORE
DEVELOPMENT

DEVELOPMENT

San Francisco

Discovery & development of first-in-class monoclonal antibody therapeutics
READ MORE
Immune Checkpoints

Immune Checkpoints

Our Pipeline

CGEN-15001T

CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells ...
READ MORE

CGEN-15022

CGEN-15022 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15022 is expressed in numerous types of epithelial cancers, such ...
READ MORE

CGEN-15049

CGEN-15049 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15049 was shown to inhibit the activity of immune cells that play ...
READ MORE

CGEN-15027

CGEN-15027 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. Studies by Compugen have shown that this immune checkpoint target is ...
READ MORE

CGEN-15052

CGEN-15052 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. Initial testing of CGEN-15052 expression in human cancer tissue samples ...
READ MORE

CGEN-15092

CGEN-15092 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15092 Fc fusion protein was shown to inhibit activation of T cells and ...
READ MORE

CGEN-15001

CGEN-15001 is our lead program for autoimmune diseases. CGEN-15001 is an Fc fusion protein that contains the extracellular domain of CGEN-15001T, a novel immune ...
READ MORE
MORE EVENTS

Collaborations

Bayer
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
Neviah
In June 2012, Compugen and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, jointly ...
Click here for more info about partnering with Compugen